The Society of Scholars was created on the
recommendation of then President Milton S.
Eisenhower and approved by the university board of trustees
on May 1, 1967. The society — the first of
its kind in the nation — inducts former postdoctoral
fellows, postdoctoral degree recipients, house
staff and junior or visiting faculty who have served at
least a year at Johns Hopkins and thereafter
gained marked distinction elsewhere in their fields of
physical, biological, medical, social or
engineering sciences or in the humanities and for whom at
least five years have elapsed since their
last Johns Hopkins affiliation. The Committee of the Johns
Hopkins Society of Scholars, whose
members are equally distributed among the academic
divisions, elects a limited number of scholars
from the candidates nominated by the academic divisions
with postdoctoral programs.

The scholars elected in 2009 will be invested at a
ceremony hosted by acting Provost Scott
Zeger at 4 p.m. on Wednesday, May 20, in Homewood's Mason
Hall. At that time, the new members will
each receive a certificate and a medallion on a
black-and-gold ribbon to be worn with academic regalia.
The induction, which brings to 536 the total number of
members in the Johns Hopkins Society of
Scholars, will be followed by a dinner hosted by President
Ronald J. Daniels. The new members will be
recognized at Commencement on May 21.

The following listing of the new Society of Scholars
members is accompanied by a short
description of their accomplishments at the time of their
election to the society.

Kenneth C. Anderson
Boston

Kenneth Anderson

Kenneth Anderson, a 1977 graduate of the School of
Medicine and an intern, fellow and resident
in the Department of Internal Medicine from 1977 to 1980,
has developed one of the world's most
successful translational research programs devoted to
multiple myeloma. As the Kraft Family
Professor of Medicine at Harvard Medical School, chief of
the Division of Hematologic Neoplasia and
director of the Jerome Lipper Multiple Myeloma Center at
Dana-Farber Cancer Institute, he has
conducted research studies that have resulted in important
new therapies for the treatment of this
cancer of the plasma cell. Specifically, Anderson's
research group played a major role in the
development of bortezomib, possibly the most effective drug
against this serious disease. Also vice
chair of the Program in Transfusion Medicine at Harvard
Medical School, Anderson has made
significant contributions to the development of cellular
therapies and minimization of the immunologic
complications of blood transfusion. In 2005, he received
the Robert A. Kyle Lifetime Achievement
Award from the International Myeloma Foundation.

Nominators: William Nelson, the Marion I. Knott
Professor and Director of the Department of
Oncology, and Richard J. Jones, professor and director of
the Hematologic Malignancies Program,
Department of Oncology, School of Medicine

Karen D. Davis
Toronto, Ontario, Canada

Karen Davis

Karen Davis published 14 papers based on her
three-year postdoctoral fellowship research,
from 1988 to 1991, in the Pain Research Laboratory at Johns
Hopkins. She has gone on to an
exemplary career at the University of Toronto, where she
now serves as head of the Division of Brain,
Imaging and Behavior-Systems Neuroscience and associate
director of the Institute of Medical
Science. She also holds the Canada Research Chair in Brain
and Behavior. Davis' laboratory has
developed innovative brain-imaging approaches, culminating
in the first functional MRI images of brain
networks underlying the human pain experience and the first
images of the impact of deep brain
stimulation for Parkinsonian tremor. Her research has
increased the understanding of pain, attention
and plasticity associated with neurological and psychiatric
disease. Davis has also created educational
programs and published the book New Techniques for
Examining the Brain.

Nominator: James N. Campbell, professor of
neurosurgery, Department of Neurology and
Neurosurgery, School of Medicine

Merrill J. EgorinPittsburgh

Merrill Egorin

An intern and resident from 1973 to 1975 who also
received his undergraduate and medical
degrees from Johns Hopkins, Merrill Egorin worked under
Victor McKusick and completed a clinical
fellowship at the Baltimore Cancer Research Center. Since
1998, he has been a professor of medicine
and of pharmacology at the University of Pittsburgh School
of Medicine. Now co-director of the
Molecular Therapeutics/Drug Discovery Program at the
University of Pittsburgh Cancer Institute,
Egorin has played a central role in defining the
pharmacokinetic/pharmacodynamic relationships of a
large number of chemotherapeutic agents currently used to
treat cancer. For example, his work has
led to a paradigm shift in the dosing of the cancer drug
carboplatin. In addition, he has pioneered the
current standards regarding evaluation of a specific group
of chemotherapy drugs in special
populations, such as patients with organ dysfunction and
the elderly.

Nominator: David S. Cooper, professor of
endocrinology, Department of Medicine, School of
Medicine

Martha S. LinetBethesda, Md.

Martha Linet

Considered a leading scientific expert in the
epidemiology of leukemia, Martha Linet is chief of
the Radiation Epidemiology Branch in the Division of Cancer
Epidemiology and Genetics at the National
Cancer Institute. She has directed landmark studies of
childhood leukemia that have focused on low-
frequency magnetic fields and radiation exposure outcomes
in the U.S. Radiologic Technologists
Cohort. Linet has also led collaborative international
studies representing the United States with the
International Agency for Research on Cancer and liaison
activities for the National Cancer Institute
to the Environmental Protection Agency and the Food and
Drug Administration. In addition, she was a
key scientific member of the advisory committee that
investigated cancer risks following the
Chernobyl accident. She has contributed substantially to
the scientific literature, including a text on
the epidemiology of leukemia. At Johns Hopkins, Linet was a
postdoctoral fellow in the Department of
Epidemiology from 1977 to 1979.

Nominator: David D. Celentano, professor and interim
chair, Department of Epidemiology, Bloomberg
School of Public Health

Victor J. MarderLos Angeles

Victor Marder

Victor Marder received undergraduate, master's and
medical degrees from Johns Hopkins and
was an intern in the Department of Medicine from 1959 to
1960. He has since led a distinguished
academic career with leadership positions at Temple
University, the University of Rochester and most
recently UCLA, where he is a clinical professor of
medicine, pediatrics and neurology in the David
Geffen School of Medicine and director of the Vascular
Medicine Service at the Los Angeles
Orthopedic Hospital. Marder's research, both basic and
translational, has focused on blood
coagulation. He conducted pioneering studies on the
interaction of fibrinogen with the fibrinolytic
agent plasmin, and his translational studies led to a new
therapy for use in venous thromboembolic
disease, heart attack and stroke. Marder's numerous
recognitions for his scientific accomplishments
include a distinguished career award from the International
Society of Hemostasis and Thrombosis.

Nominator: Jerry L. Spivak, professor of medicine
and oncology, School of Medicine

Joel MossBethesda, Md.

Joel Moss

Currently deputy chief of the Translational Medicine
Branch of the National Heart, Lung and
Blood Institute at the National Institutes of Health, Joel
Moss was an intern and resident in the
Johns Hopkins Department of Medicine from 1972 to 1974.
Since then, he has consistently engaged in
pioneering research and is now an acknowledged leader in
the field of biochemistry. His initial studies
focused on cholera toxin, the protein responsible for fluid
and electrolyte losses characteristic of
cholera, and he added to the understanding of how that
protein operates. More recently, Moss has
been involved in research on deadly lung diseases,
including a rare disorder known by the acronym
LAM. He holds several patents and has published a number of
texts, one of which is a volume that
describes the structure and function of bacterial toxins.
In recognition of his accomplishments, Moss
has received the Passano Foundation Young Investigator
Award, the AFCR Young Investigator Award
and the LAM Foundation Award.

Bernd Nowack is internationally recognized for his
imaginative contributions toward
understanding the interactions of natural and synthetic
chemicals with particulate matter. His work
with detergent builders and other synthetic chelating
agents has aided European Union reappraisals of
their safety. While at the Institute of Terrestrial
Ecosystems, he pioneered methods for
documenting chemical assimilation by plant roots.
Presently, Nowack leads the Materials, Products and
the Environment Group at the Swiss Institute for Materials
Science and Technology. There he is
developing innovative approaches toward predicting
transformations and the ultimate impact of
engineered nanoparticles in environmental media. He has
been a key organizer of influential
international conferences and workshops on environmental
chemistry, nanoparticle science and
technology, and biogeochemistry. At Johns Hopkins, Nowack
was a postdoctoral fel-low in the
Department of Geography and Environmental Engineering from
1997 to 1998.

Thomas Pearson received his medical degree, master's
degree in public health and doctoral
degree in cardiovascular epidemiology from Johns Hopkins,
where he also completed residencies in
preventive medicine and internal medicine and a fellowship
in cardiology. Today, he is widely
recognized as a leader in public health research and,
specifically, in the epidemiology and prevention of
atherosclerotic cardiovascular disease. Pearson is the
Albert D. Kaiser Professor in the Department of
Community and Preventive Medicine and senior associate dean
for clinical research at the University
of Rochester. With a long-standing interest in
international trends in cardiovascular disease and
stroke, Pearson was one of the first to identify the spread
of coronary diseases in developing
countries. His research at the patient, health care system,
community and public policy levels has
helped develop guidelines in preventive cardiovascular
disease and has contributed significantly to the
incorporation of new knowledge and approaches to the
education of the public and various health care
groups.

Nominator: Leon Gordis, professor, Department of
Epidemiology, Bloomberg School of Public Health

Jennifer A. PietenpolNashville,
Tenn.

Jennifer Pietenpol

A fellow in the Oncology Center at Johns Hopkins from
1991 to 1994, Jennifer Pietenpol is now
the B.F. Boyd Jr. Professor of Molecular Oncology and
professor of biochemistry, cancer biology and
otolaryngology at the Vanderbilt University School of
Medicine. She has made major contributions to
our understanding of the p53 signaling network. The p53
gene is altered in numerous forms of cancer-
-including those of the breast, colon, lung, brain,
pancreas and stomach — and is the most frequently
altered cancer gene yet identified. Pietenpol has helped
discover how p53 and related genes work to
make cells grow abnormally and, in particular, how they
divide so quickly and die so slowly. Her
research seeks not only to define these mechanisms but also
to use this information to advance
patient care. Pietenpol plays a major role in charting the
directions of cancer research in the United
States as director of the Vanderbilt-Ingram Cancer Center
and as a presidentially appointed member
of the national Cancer Advisory Board.

Nominators: Nancy Davidson, Breast Cancer Research
Professor in Oncology, and Bert Vogelstein,
Clayton Professor of Oncology and Pathology, School of
Medicine

James PiscatoriCanberra,
Australia

James Piscatori,

James Piscatori is a leading interpreter of
international political Islam of the fundamentalist
variety. His work explores the transnationalism of Islam,
moving attention away from its place within
individual societies and highlighting the ties between
Muslim history, sociology and politics. Originally
working in Islam in international law, Piscatori developed
interests in Islamic fundamentalism during
his stint as an associate professor at the Johns Hopkins
Nitze School of Advanced International
Studies from 1986 to 1989, well before the events of Sept.
11, 2001, turned the world's attention to
the phenomenon. Piscatori was a fellow in the Center for
Islamic Studies at Oxford University before
assuming his current position as deputy director of the
Centre for Arab and Islamic Studies at the
Australian National University.

As a postdoctoral fellow working with Colin Norman in
the Center for Astrophysical Sciences at
Johns Hopkins from 1984 to 1986, Ralph Pudritz wrote papers
on outflows from protostars that are
still widely cited classics. His career has continued on a
brilliant path. He is a world-renowned expert
on star formation, astrophysical jets and outflow, and the
properties of molecular clouds. He chaired
the 2000 Canadian Decadal Survey for Astronomy, the most
comprehensive survey ever undertaken in
Canadian astrophysics. Its recommendations ultimately made
Canada an active partner for new
observatories, such as the Atacama Large Millimeter Array,
the James Webb Space Telescope and
the Thirty Meter Telescope. In 2004, Pudritz founded the
Origins Institute at McMaster University,
which he directs today. The institute focuses on research
in transdisciplinary fundamental science,
and it is now a significant research center for
astrobiology. With numerous major papers and books to
his credit, Pudritz gives presentations frequently on star
and planet formation and, more recently,
astrobiology.

Anne Taylor is an established researcher whose
extensive body of work has focused on
cardiovascular diseases in minorities and women. She has
also been instrumental in the transfer of
knowledge about cardiovascular disease prevention from the
realm of research to the community.
From 2001 to 2005, Taylor chaired the steering committee
for the African-American Heart Failure
Trial, which was a landmark research effort that tested the
effectiveness of a heart failure
medication in a specific ethnic population. The results of
the study have contributed significantly to
human health and to the opportunity to understand further
the influence of ethnicity on disease and
life-saving achievement strategies. A research fellow in
the Johns Hopkins Department of Cardiology
from 1981 to 1982, Taylor is the vice dean for academic
affairs and professor of medicine in
cardiology at the Columbia University College of Physicians
and Surgeons. She has been recognized
with many awards and honors and is further distinguished
because of her demonstrated administrative
ability in a variety of settings.

Nominator: Myron L. Weisfeldt, the William Osler
Professor of Medicine and chairman, Department of
Medicine, School of Medicine

Donald L. TrumpBuffalo, N.Y.

Donald Trump

A 1970 graduate of the Johns Hopkins School of
Medicine, Donald Trump completed an
internship and residency training in medicine and a
fellowship in oncology at The Johns Hopkins
Hospital from 1970 to 1974, served as chief resident in
internal medicine from 1974 to 1975 and was a
member of the cancer center faculty from 1977 to 1981.
Trump's distinguished academic career
includes leadership roles at several premier cancer centers
as well as his current position as president
and CEO of the Roswell Park Cancer Institute in Buffalo,
N.Y. Trump is a national and international
authority in the treatment of prostate cancer and other
genitourinary cancers. In particular, he has
made major contributions to the field of new anticancer
drug development and has added significantly
to our understanding of the role of vitamin D in the
pathogenesis and treatment of cancer.

Nominators: William Nelson, the Marion I. Knott
Professor and Director of the Department of
Oncology, and Ross C. Donehower, the Virginia and D.K.
Ludwig Professor in Clinical Investigation of
Cancer, Department of Oncology, School of Medicine

Lai-Xi WangBaltimore

Lai-Xi Wang

Lai-Xi Wang is an associate professor in the
Department of Biochemistry and Molecular Biology
in the Institute of Virology at the University of Maryland
School of Medicine. His research has
provided important new insights for HIV vaccine design and
propelled him to the forefront of the
anti-HIV field. Specifically, he has explored carbohydrate
antigens as a target for an HIV vaccine by
synthesizing novel oligosaccharides (saccharide polymers)
to mimic the antigens on the viral envelope.
Wang has also developed a highly efficient method for
making glycoproteins that carry defined
oligosaccharides, a process that opens a new avenue for
rapid access to various glycoproteins that are
essential for probing the structure and function of this
class of important biological molecules. In
recognition of his achievements, Wang received the 2004
Young Investigator Award in Carbohydrate
Chemistry from the American Chemical Society. Wang was a
postdoctoral fellow at Johns Hopkins in
the Department of Biology from 1993 to 1997.

Arnold-Peter Weiss received his undergraduate and
medical degrees from Johns Hopkins and
was an intern and resident in the departments of General
Surgery and Orthopaedic Surgery from
1985 to 1990. Today, he is known throughout the world as an
accomplished hand surgeon, excellent
educator and ingenious innovator. Weiss specializes in hand
and wrist reconstruction with a special
interest in finger- and wrist-joint replacement surgery. He
holds eight patents for novel surgery
techniques and equipment, including a new carpal tunnel
release procedure and joint replacement
implants. Weiss is associate dean of medicine and dean of
admissions at Brown University's Warren
Alpert Medical School. He has been honored with the
America's Top Doctors, Best Doctors in America
and America's Top Surgeons awards. He has also been a
distinguished leader in many orthopedic
organizations, such as the American Society for Surgery of
the Hand and the American Board of
Orthopaedic Surgery. He is editor of the two-volume text
Hand Surgery.

Nominator: Frank J. Frassica, the Robert A. Robinson
Professor and chair, Department of Orthopaedic
Surgery, School of Medicine